Personalizing Therapy for Patients With CML

Michael J. Mauro, MD

Video Categories: CML

Dr. Mauro addresses the debate over selecting first line therapy with three approved agents available.
July 25, 2018

How MSI and TMB Factor into Current Biomarker Testing Panels

Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”

August 15, 2016

Carcinoid Heart Disease

Richard Parker, MD, provides an overview of this condition, which is common on patients with carcinoid syndrome.